INTRODUCTION
Aberrant epigenetic patterning is a cornerstone of the molecular pathogenesis of cancers, including myeloid malignancies. 1 DNA methyltransferase 3A (DNMT3A) mutations are detected in 8-10% of myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS), [2] [3] [4] and in 20-25% of acute myeloid leukemias (AMLs). [5] [6] [7] [8] These mutations occur as monoallelic or biallelic nonsense/frameshift alterations, or a dominant-negative R882 substitution. 9,10 DNMT3A-mutant AMLs exhibit global and sitespecific alterations in DNA methylation, 10 also observed in chronic myelomonocytic leukemia (CMML) patients with DNMT3A mutations. 11 Although these data underscore the importance of DNMT3A mutations to myeloid transformation, the specific mechanisms by which DNMT3A functions as a tumor suppressor have not been fully elucidated. It is possible that mutations in epigenetic modifier genes alter the epigenetic state of normal hematopoietic stem/ progenitor cells (HSPCs), which allows malignant cells to re-access earlier developmental transcriptional programs. Notably, features such as enhanced hematopoietic stem cell self-renewal, increased proliferative capacity, myeloid bias and extramedullary hematopoiesis (EMH) are shared between fetal liver hematopoiesis and MDS/MPN. 12, 13 Previous studies on Dnmt3a loss in adult hematopoiesis used transplantation assays to document expansion of the stem/ progenitor compartment, most prominently long-term HSCs, a gain in self-renewal and a decline in the output of differentiated progeny. 14 Moreover, a subset of recipients developed different hematologic malignancies. 15, 16 However, these studies did not assess the tumor suppressor function of Dnmt3a in the absence of the selective pressure of serial transplantation, or whether Dnmt3a loss is sufficient to induce transformation in vivo. We therefore characterized the impact of conditional Dnmt3a loss in the hematopoietic compartment to assess the impact on disease phenotype in vivo, and on steady-state adult hematopoiesis, coupled with studies of the effect of Dnmt3a loss on DNA methylation and transcriptional state.
MATERIALS AND METHODS
Animal studies were approved by the Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center. Dnmt3a f/f conditional knock-out (cKO) line 17 was reconstituted from frozen embryos (The Jackson Laboratory, Bar Harbor, ME, USA), backcrossed to C57BL/6 background and crossed to Mx1-Cre-deletor line. See supplementary methods.
Colony-forming assay in semisolid media was performed using previously published method 18 with modifications. See supplementary methods.
Homing assay was performed as described 19 with modifications. See also supplementary methods.
Gene expression and DNA methylation analyses were performed on FACS-sorted Lineage -Sca-1 + c-Kit + (LSK) and granulocyte/macrophage progenitor (GMP) cells. ERRBS (Enhanced Reduced Representation of Bisulfite Sequencing) was used to determine cytosine methylation patterns at base pair resolution. 20, 21 RNA was subjected to standard Illumina-based sequencing. For detailed description, see supplementary methods.
Statistical analysis
Except where indicated, data are presented as mean ± standard deviation plotted using Prism version 6 (GraphPad Software Inc., La Jolla, CA, USA).
Statistical significance was determined using the Student's t-test with Holm-Sidak correction method, with α = 5.0%.
RESULTS

Hematopoietic-specific inactivation of Dnmt3a results in lethal hematologic disease
We first investigated the role of Dnmt3a in steady-state hematopoiesis. Mx1-Cre-driven recombination results in complete loss of Dnmt3a protein in the hematopoietic system (Figure 1a and Supplementary Figure S1A ) and leads to a lethal, fully penetrant disease (median survival 48.6 weeks, Cre-mediated excision was induced by poly(I:C) injections (please see Supplementary Methods). Animals used as controls for diseased Dnmt3a-KO mice were censored. Reasons for euthanasia in two control animals were rectal prolapse and severe bite wounds due to fighting; cause of death in one mouse was undetermined. None of the control mice exhibited signs of hematologic disease. (c) White blood cell counts at disease onset in Dnmt3a-ablated mice (n = 6-7). (d-h) Dnmt3a-deleted mice develop macrocytic anemia (n = 6-7) with decreased hematocrit (d) and hemoglobin levels (e), increased mean corpuscular volume (f), thrombocytopenia (g) and anisocytosis (h) (**P o0.01; ***Po 0.001). (i-j) Hematocrit (i) and platelet counts (j) over time in six Dnmt3a-KO and four representative control mice. Dnmt3a loss induces mature myeloid and myeloid progenitor expansion in vivo Detailed analysis of the hematopoietic system in Dnmt3a-KO mice found marked myeloid bias and myeloid and erythroid dysplasia in peripheral blood (Figures 2a and b ) accompanied by hypercellular bone marrow (Supplementary Figure S2A ) with megakaryocyte dysplasia (Figure 2c ). We found increased spleen size ( Figure 2d ) and effacement of splenic architecture by myeloid infiltration, and scattered dysplastic megakaryocytes (Figure 2e ), consistent with myeloproliferation, confirmed by flow cytometry (Figure 2f and Supplementary Figure S2B ). We observed an increase in the stem cell-enriched LSK and in Lineage -Sca-1c-Kit + myeloid progenitor cells, with significant expansion of GMPs (Figures 2g and h) . The findings of hypercellular bone marrow with dysplasia, myeloid bias in the peripheral blood and EMH are consistent with a myeloproliferative/myelodysplastic disorder (MDS/MPN).
Impaired erythroid maturation after Dnmt3a loss
To gain insight into the mechanism of anemia in diseased Dnmt3a-null mice, we examined erythroid maturation in bone marrow and spleens according to CD71 and Ter119 markers 22, 23 and found a decrease in the mature stage IV erythroblasts and an increase in stage II CD71 + Ter119 + cells, most pronounced in the spleens, without significant changes in apoptosis (Supplementary Figures S2C-E), consistent with a previous report. 15 We also observed erythrophagocytosis in the spleens and livers of Dnmt3a-deleted animals (Supplementary Figure S2F ).
Perturbation of the stem/progenitor compartment and increased self-renewal of Dnmt3a-deficient hematopoietic cells Previous studies found increased numbers of primitive HSCs, but not of immediate downstream progenitors, in recipient mice reconstituted with Dnmt3a-ablated HSCs. 14 In this setting, the impact of stress from bone marrow transplantation could not be unequivocally separated from the cell-intrinsic HSC phenotype. Detailed analysis of HSPCs in diseased primary Dnmt3a-KO animals showed a significant increase in the relative frequency of the immature LSK population. This expansion was due to elevated LSK CD48 + cells while the LSK CD48 -CD150 + LT-HSC population remained unperturbed, and we observed an increase in committed myeloid progenitors ( Figures 3a and b and Supplementary Figure S3A ). Overall, Dnmt3a-deficient HSPCs were characterized by increased proliferation and decreased apoptosis (Figures 3c and d) . The increased frequency of CD48 + LSK cells accompanied by predominant myelopoiesis relative to lymphopoiesis, and increased self-renewal and multi-lineage reconstitution potential are characteristic of fetal hematopoiesis. 13 We observed a prominent cKit + CD41 + population in the bone marrow of Dnmt3a-deleted mice, which is nearly absent in normal adult hematopoiesis (Supplementary Figure S2G) .
To assess the self-renewal potential of bone marrow cells, we performed colony-forming assays. Dnmt3a loss resulted in continuous serial replating, while control cells rapidly exhausted their colony-forming ability (Figure 3e ). In serial competitive transplantation assays in vivo Dnmt3a-KO cells showed robust repopulation advantage compared with wild-type control ( Supplementary Figures S3B and C) , which was more pronounced in the bone marrow compartment, and continued to increase with each round of transplantation (Figures 3f and g) . These observations suggest that loss of Dnmt3a augments stem cell function in vitro and in vivo.
Dnmt3a loss results in hepatomegaly due to liver-specific myeloproliferation and EMH All moribund Dnmt3a-deleted animals presented with distended abdomens and marked hepatomegaly (Figures 4a and b ). Histopathologically Dnmt3a-KO livers showed portal, lobular, sinusoidal infiltration by immature myeloid cells with open chromatin and prominent nucleoli, scattered megakaryocytes and occasional blasts (Figure 4c ), confirmed by FACS analysis that also showed prominent monocytosis (Figures 4d and e and Supplementary Figure S4A ). Alkaline phosphatase and bilirubin levels were elevated and albumin levels decreased (Figure 4f and Supplementary Figure S4B ), consistent with impaired liver function.
Histological detection of megakaryocytes in infiltrated liver parenchyma after Dnmt3a inactivation suggested that liver was a site of hematopoiesis. Analysis of HSPCs residing in the liver detected myeloid progenitor Lineage -Sca-1c-Kit + and stem cellenriched LSK cells in Dnmt3a-null mice, but not in wild-type animals (Supplementary Figure S4C ). Plating of Dnmt3a-KO liver cells yielded colonies with characteristic granulocyteerythroid-macrophage-megakaryocyte and granulocyte-macrophage morphology that serially replated ( Figure 4g ) similar to continuously self-renewing Dnmt3a-ablated bone marrow cells. By contrast, cells derived from wild-type control livers were unable to give rise to hematopoietic colonies in vitro.
Dnmt3a-deleted bone marrow cells exhibit cell-intrinsic liver tropism
As Mx1-Cre is able to mediate excision, in addition to HSCs, in hepatic and perivascular cells, 24, 25 we examined whether extramedullary tropism of Dnmt3a-KO hematopoietic cells was due to cell-intrinsic or niche-dependent mechanism by performing short-term homing studies (Figure 5a ). Although the ability of Dntm3a-deficient cells to home to the bone marrow was unaltered, they showed preferential liver tropism (Figures 5b and c). Interestingly, CD45 + Dnmt3a-KO liver cells exhibited even stronger hepatotropism than bone marrow cells from the same animals (Supplementary Figure S5A ). These findings demonstrate that preferential liver homing of Dnmt3a-null hematopoietic cells is mediated by a cell-intrinsic mechanism.
Hematopoietic-specific Dnmt3a loss results in cell-autonomous myeloproliferation and liver-specific myeloid expansion in secondary recipients We tested the ability of Dnmt3a-deficient hematopoietic cells to re-initiate MDS/MPN by transplantation into sublethally-irradiated congenic hosts. No engraftment was observed 12 weeks post transplant confirming that the hematologic disease represents MDS/MPN, and not AML. Conversely, transplantation into lethallyirradiated recipients resulted in a fully penetrant, rapidly fatal disease with a median latency of 13.4 weeks (Figure 5d , P o0.0001) that recapitulated the MDS/MPN seen in primary mice with hepatosplenomegaly ( Figure 5e and Supplementary Figure S5B ). Similar results were obtained when recipient mice were transplanted with CD45 + cells isolated from Dnmt3a-deleted livers, suggesting that disease-initiating cells are present in the liver (data not shown). Dnmt3a-KO-transplanted livers showed myeloid infiltration and histiocytic hyperplasia (Figure 5f ). Recipient mice developed thrombocytopenia, decreased hematocrit and peripheral blood leukocytosis with monocytosis ( Figures 5g and h and Supplementary Figures  S5C and D) . In contrast to primary Dnmt3a-KO mice, transplant recipients showed both myeloid and T-lymphoid bias, and bi-lineage expansion ( Supplementary Figures S5E and F) .
EMH in MDS/MPN patients with DNMT3A mutations
To extend our studies to the human context, we examined whether DNMT3A mutations are associated with EMH in a wellannotated cohort of 46 patients with the MDS/MPN overlap syndrome CMML. 11 DNMT3A-mutant patients had a higher rate of clinically evident EMH (Figure 5i ): two of four DNMT3Amutant patients (50%) presented with hepatosplenomegaly and lymphadenopathy due to extramedullary CMML, while only 7.14% (3/42) DNMT3A-WT patients showed similar extramedullary involvement (P = 0.053 and Phi = +0.39, two-tailed Fisher's exact test). These data underscore the tumor suppressor role of Dnmt3a and association of DNMT3A loss with EMH in the clinical context.
DNA methylation profiling reveals decreased methylation upon
Dnmt3a loss at loci with regulatory potential To assess whether the Dnmt3a-KO phenotype was linked to aberrant epigenetic programming, we analyzed DNA methylation patterns in LSK and GMP cells. ERRBS followed by unsupervised hierarchical clustering of genome-wide cytosine methylation profiles showed segregation of Dnmt3a wild-type and mutant samples (Supplementary Figure S6A) . Genome-wide CpG (Figure 6a ; Po 0.01, Wilcoxon two-tailed rank-sum test). Of the 822 differentially methylated regions (DMRs) in GMPs (DMRs-methylKit: qo0.01 and ⩾ 20% methylation difference; methylSig: beta-binomial P ⩽ 0.25 and methylation difference ⩾ 10%; Supplementary Table S1 ), 797 (97%) were hypomethylated in Dnmt3a-ablated mice (Supplementary Figure  S6B) with particular enrichment for hypomethylated CpGs within introns, gene neighborhoods and intergenic regions (P o 0.01, one-tailed Fisher's exact test; Figure 6b ). We next focused our analyses on GMPs as we observed a marked increase in the proportion of GMPs in vivo. A trend toward hypomethylation was seen at gene promoters (Figure 6b and Supplementary Figure S6C ). Overall, GMP-stage active enhancers showed a greater degree of methylation loss than promoters, exons, introns, gene neighborhoods or intergenic regions (P o 0.01, Wilcoxon one-tailed rank-sum test with continuity correction; Figure 6c) . A subset of genes associated with hypomethylated DMRs had increased expression by the RNA-sequencing analysis (Supplementary Figure S6E ). Furthermore, in GMPs significantly hypomethylated regions were enriched in binding sites with homology to Ets family transcription factor Elk4, zinc finger and BTB domain containing transcription factor Zbtb3, and Forkhead class transcription factor FoxP1, implicated as tumor suppressors, while HoxA9 was among notable findings in LSKs (Supplementary Figure S6D ). [26] [27] [28] Gene ontology analysis by biological process applied to DMCs within gene promoters revealed significant enrichment of genes involved in cell adhesion (CD97, Icam2, Ppard, Cldn4, Eng, Ninj2, protocadherins and cadherin-related protein genes), regulation of RNA polymerase II-driven transcription (Srebf1, FoxH1, HoxB1, Cebpb, Hand1, Nr4a2, Tead2 and Jak3) and embryonic development (HoxB1, Cebpb, Hand1, Hlx, HoxA6 and HoxB6; Figure 6e ). These data suggest that the hypomethylation observed with Dnmt3a loss may have a functional role in regulating transcriptional gene states.
Gene expression profiling identifies reprogramming toward a more primitive developmental state with Dnmt3a loss RNA sequencing identified 218 upregulated and 98 downregulated genes in Dnmt3a-null GMPs (Figure 6d ; adjusted Po 0.1), including genes implicated in embryonic and cancer stem cell phenotypes cMyc, 29 Lifr, 30 Bmx, 31 Satb1, 32 positive and negative regulators of tumor invasion Adam3, Ptk7, 33 serpin 34 and semaphorin 35 family proteins and ephrin receptor ligands, and networks associated with hematopoietic cell lineage, cell surface receptors and regulation of immune systems (Figure 6f and Supplementary Figure S6F , Supplementary Table S2 ). Among hypomethylated genes that showed corresponding expression changes, in addition to Adam3 and Ptk7, were Svep1, Hivep2, Lrp1, Cds1, Padi1 and Zfp618 that regulate cell attachment and amplify cellular signaling responses from cytokines. Gene set enrichment analysis found enrichment of HSC signature genes 36 in Dnmt3a-null GMPs consistent with enhanced self-renewal. Comparison with the fetal hematopoiesis gene expression signature 37 (Figure 6g ) along with positive enrichment for PRC2-regulated genes and negative enrichment for the ES cell differentiation genes confirmed transcriptional reactivation of early developmental programs after Dnmt3a loss. In line with the previous reports 6, 38 we found increased expression of Hox genes and of their targets in Dnmt3a-null GMPs ( Supplementary Figures S6G and H) . Increased expression of the cell adhesion molecules is consistent with hypomethylation within their promoters and altered cell tropism of the Dnmt3a-ablated bone marrow cells (Figure 6e and Supplementary Figure S6H) . These data indicate that key regulatory genes and gene networks are transcriptionally modified by Dnmt3a loss. 
DISCUSSION
Our findings emphasize the crucial role of Dnmt3a in the pathogenesis of hematologic malignancies, by showing Dnmt3a loss in primary mice gives rise to a fully penetrant, lethal myeloid disease. Although studies of Dnmt3a-deficient hematopoiesis in adoptive transfer experiments have produced invaluable insights, [14] [15] [16] the variable impact on disease phenotype may be due to the selective pressure of transplantation, which has been suggested to be necessary to unmask the malignant transformation induced in Dnmt3a-deficient HSCs. 15 Our data provide an unequivocal role for Dnmt3a in inducing myeloid transformation in primary mice in the absence of transplantation. Our studies and previous studies relied on interferon-activated Mx1-Cre excision, [14] [15] [16] which may force HSCs to enter cell cycle. 39, 40 Hence, an inflammatory component may be an important contributing factor into the pathogenesis of hematopoietic failure syndromes, consistent with clinical observations. 41 Dnmt3a loss resulted in expansion of the immature compartment in the bone marrow, including LSK and GMP cells, concomitant with pronounced monocytosis. This pattern of quantitative changes reveals compromised differentiation at several stages, paralleling high-risk subtypes of MDS and a disproportionate association of DNMT3A mutations with monocytic disease observed in the clinic. 42, 43 These findings reinforce the clinical relevance of Dnmt3a-deficient hematopoiesis as a faithful animal model of human disease, including MDS/MPN.
Dnmt3a-deficient hematopoiesis shares similarities with HSC expansion within the fetal liver, including expansion of CD48 + LSK ST-HSCs and MPPs and lower relative frequencies of CD150 + CD48 -LSK LT-HSCs, preferential myelopoiesis with lower Gr-1 expression and changes in erythroid maturation, including a prominent CD41 + cKit + population not found in adult hematopoiesis. Most importantly, deletion of functional Dnmt3a leads to robust gain in self-renewal and long-term multi-lineage reconstituting potential, which is a hallmark of fetal hematopoiesis. 13, 37, 44, 45 We observed enrichment of the HSC and fetal liver gene expression signatures in Dnmt3a-null GMPs, along with upregulation of embryonic and cancer stem cell-associated genes. It is tempting to speculate that these phenotypic changes arise due to partial reprogramming toward developmentally more primitive state by impaired epigenetic control following Dnmt3a loss. Further studies examining expression of fetal stem/progenitor markers and transcriptomic switches will be necessary to address the potential role of Dnmt3a function in hematopoietic development.
The most striking finding in Dnmt3a-deleted myeloproliferation/ myelodysplasia is the hepatomegaly due to EMH and liver-specific myeloproliferation. The ability of adult hematopoietic cells to home, colonize and mature in the liver reflects primitive developmental patterns of hematopoiesis and re-establishment of a stem cell niche. 46 Reminiscent of fetal hematopoiesis, hepatic EMH in Dnmt3a-null animals was predominantly localized within sinusoids. The mechanism of homing to the liver is distinct from other organs, as the lower blood flow and fenestrated endothelium in the sinusoids do not require selectin-mediated rolling for leukocyte recruitment, suggesting that other adhesion mechanisms have a prominent role. 47 Gene expression analysis of Dnmt3a-deleted GMPs identified enrichment of a cell adhesion signature that may account for the enhanced liver tropism. At the same time, elevated expression of the extracellular matrix degradation and tissue invasion genes may contribute to cell mobilization from the bone marrow to the liver, 48,49 facilitated through epigenetic changes after Dnmt3a loss targeting genomic loci with regulatory potential, including Ets binding sites. 50 These observations may have important implications for the treatment of DNMT3A-mutated MDS in humans as EMH in the liver may serve as a safe haven environment and a reservoir for the diseaseinitiating clone. Future interrogation of the specific cell adhesion determinants will help clarify molecular mechanisms of hepatotropism of Dnmt3a-ablated hematopoietic cells.
Taken together, Dnmt3a inactivation in primary animals leads to the development of a myeloid malignancy with features of human MDS/MPN, highlighting the relevance of this model to chronic myeloid neoplasms. We speculate that increased epigenetic plasticity allows reactivation of developmental gene expression programs. Subsequent studies are needed to explore the role for concomitant disease alleles, and to determine whether therapies can be developed to prevent and/or reverse the myeloid transformation induced by Dnmt3a loss.
